预约演示

更新于：2026-04-03

Bevacizumab

贝伐珠单抗

更新于：2026-04-03

概要

基本信息

药物类型

单克隆抗体

别名

Bevacizumab(Genetical Recombination)、rhuMAb-VEGF、贝伐单抗

+ [17]

靶点

VEGF-A

作用方式

抑制剂

作用机制

VEGF-A抑制剂(血管内皮生长因子A抑制剂)、血管生成抑制剂

治疗领域

肿瘤神经系统疾病消化系统疾病+ [11]

在研适应症

不可切除的肝细胞癌肝细胞癌复发性胶质母细胞瘤+ [204]

非在研适应症

异戊酸血症急性嗜碱性粒细胞白血病急性嗜酸细胞白血病+ [295]

原研机构

Genentech, Inc.

在研机构

Hoffmann-La Roche, Inc.Merck Sharp & Dohme LLC

National Cancer Institute

+ [27]

非在研机构

NSABP Foundation, Inc.

Alliance Foundation Trials LLC

The Fox Chase Cancer Center

+ [52]

权益机构

Roche Korea Co., Ltd.

Immune-Onc Therapeutics, Inc.

Roche Holding AG

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (2004-02-26),

结肠癌直肠癌

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

Sequence Code 41632H

来源: *****

Sequence Code 41637L

来源: *****

关联

3,504

项与贝伐珠单抗相关的临床试验

NCT07288034

/ Not yet recruiting临床2期IIT

Immunotherapy Biomarker Collection for Metastatic NSCLC to Inform Adaptive Personalized Models Targeting Resistance (IMMUNO-BIOMAP)

This phase II trial tests the impact of biomarkers in predicting initial treatment (first-line) PD1 or PD-L1 (PD[L]-1)-based immunotherapy response and in selecting second-line treatment in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Response and survival rates in advanced stage NSCLC, unlike other cancers, rely on response to first-line therapy. Immunotherapy with PD(L)1-based therapy, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. While immunotherapy has improved survival rate, the prognosis remains poor with most patients receiving chemotherapy after immunotherapy. Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid (DNA) which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. The first part of this trial, studying samples of blood and tissue in the laboratory from patients receiving immunotherapy may help doctors learn more about the effects PD(L)1-based therapy on cells. It may also help doctors understand how well patients respond to treatment and may help develop new individualized treatment strategies. The second part of this trial also tests the effect of second-line immunotherapy, such as tremelimumab and durvalumab or adagrasib and bevacizumab, in treating patients with NSCLC with specific genetic mutations that is growing, spreading or getting worse (progressive). Tremelimumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adagrasib, a type of targeted therapy, may stop the growth of tumor cells by blocking a protein needed for tumor cell growth and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving second-line immunotherapy, tremelimumab and durvalumab or adagrasib with bevacizumab, may be safe, tolerable, and/or effective in treating patients with stage IIIB/IV NSCLC with specific genetic mutations.

开始日期2026-09-21

申办/合作机构

City of Hope National Medical Center

[+1]

NCT07504588

/ Not yet recruiting临床2期IIT

A Randomized Phase II Trial of Sacituzumab Govitecan (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.

开始日期2026-09-10

申办/合作机构

National Cancer Institute

NCT07500298

/ Not yet recruiting临床1期IIT

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

To learn if SAR445877 in combination with FOLFOX6 and bevacizumab can be safely given to patients with advanced MSS CRC.

开始日期2026-09-03

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

100 项与贝伐珠单抗相关的临床结果

登录后查看更多信息

100 项与贝伐珠单抗相关的转化医学

登录后查看更多信息

100 项与贝伐珠单抗相关的专利（医药）

登录后查看更多信息

19,901

项与贝伐珠单抗相关的文献（医药）

2026-12-31·mAbs

Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection

Article

作者: Gillard, Marianne ; Marcellin, Esteban ; Gunter, Helen ; Chavalparit, Thornwit ; Barry, Craig ; Mercer, Timothy

Messenger RNA (mRNA) has emerged as a powerful tool for protein expression in clinical settings, yet its potential as a platform for biologics manufacturing remains underexplored. Here, we evaluate transient mRNA transfection in Chinese hamster ovary (CHO) cells as a rapid and versatile system for protein production. Using reporter mRNAs, we optimize transfection efficiency and benchmark performance against industry-standard plasmid transfection and stable cell line methods. We demonstrate that co-transfection of heavy and light chain mRNAs enables the efficient synthesis, assembly and secretion of the monoclonal antibody bevacizumab with high fidelity. Compared to conventional approaches, mRNA transfection drives rapid and predictable protein expression, reducing cell incubation times and enabling sequential or conditional expression. These features highlight mRNA as a flexible and efficient platform for transient expression, providing a foundation for accelerating the development and manufacturing of biologics.

2026-12-31·ANNALS OF MEDICINE

Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis

Review

作者: E., Shaolong ; Ying, Tianshu ; Ying, Huanchun

BACKGROUND:

Although single-agent chemotherapy is the most common approach for treating platinum-resistant or refractory ovarian cancer (PROC), there is growing evidence that combining molecular targeted agents with chemotherapy is beneficial, especially for certain patient groups. However, the most effective combination regimen remains elusive.

OBJECTIVES:

This Bayesian network meta-analysis (NMA) aims to identify the best combination therapy for PROC.

METHODS:

Relevant studies were searched in PubMed, EMBASE, Web of Science and the Cochrane Central Register of Controlled Trials from their inception until October 2024. The primary outcomes were overall survival (OS), progression-free survival (PFS) and adverse events (AEs). Statistical analyses were performed using the GEMTC package (1.0-2) and R 4.2.0. This review was registered in PROSPERO (CRD42023428414).

RESULTS:

Our analysis of 22 randomized controlled trials (RCTs) (n = 3408) demonstrated that chemotherapy combinations with bevacizumab (hazard ratio (HR) = 0.52-0.65), sorafenib (HR = 0.65, 95% confidence interval (CI): 0.45-0.93) or adavosertib (HR = 0.56, 95%CI: 0.35-0.90) significantly improved OS and PFS versus chemotherapy alone. Notably, adavosertib + gemcitabine was associated with an increased risk of grade 3-4 AEs (relative risk (RR) = 1.8, 95%CI: 1.3-2.7), but these were generally manageable.

CONCLUSIONS:

Bevacizumab-based combinations demonstrate consistent benefits across multiple regimens for PROC. Paclitaxel + bevacizumab emerges as the optimal balance of efficacy and safety. Topotecan + sorafenib could be an alternative for patients who are ineligible for anti-angiogenic therapy.

2026-06-01·BIOSENSORS & BIOELECTRONICS

MASEA: A microfluidic system for in situ evaluation of tumor angiogenesis in PDO–endothelial co-culture

Article

作者: Liang, Naixin ; Wei, Zewen ; Gao, Chao ; Lin, Yuxiao ; Wu, Xin ; Wang, Daoyun ; Zhang, Nan ; Yu, Kang ; Gao, Mingyao ; Zheng, Zhibo ; Qin, Yuzhi ; Wang, Zhina ; Huang, Zhicheng

Patient-derived organoids (PDOs) are promising preclinical models for personalized cancer therapy, but quantitative, time-resolved assessment of PDO-vascular interactions remains difficult. We developed MASEA, an automated microfluidic platform integrating real-time pneumatic fluid control, a PDO culture module, and a custom co-culture/sensing microfluidic chip (MEA-Chip). The system supports perfused PDO-endothelial co-culture in a confined 3D microenvironment and enables in situ measurement of pro-angiogenic factors using a bead-based biosensor, together with standardized image-based quantification of vascular networks. We evaluated MASEA using six lung cancer patient-derived PDO lines co-cultured with HUVECs. Angiogenesis was monitored over 60 h and quantified using total length (TL), number of junctions (NJ), total segment length (TSL), and total mesh area (TMA), while VEGF dynamics were measured in parallel. Across the cohort, co-culture consistently enhanced vascular network formation and increased VEGF levels compared with HUVEC-only controls. Treatment with bevacizumab reduced both angiogenic metrics and VEGF accumulation, demonstrating time-resolved assessment of anti-angiogenic responses. These results establish MASEA as an integrated assay for quantitative analysis of tumor-vascular interactions and for patient-specific screening of anti-angiogenic therapies under controlled microenvironmental conditions.

4,251

项与贝伐珠单抗相关的新闻（医药）

2026-04-02

·FiercePharma

Another AstraZeneca Emerald glimmers as Imfinzi, Imjudo delay liver cancer progression

The Emerald-3 showing draws a resemblance to AstraZeneca’s Emerald-1 readout in the same locoregional treatment setting among liver cancer patients eligible for TACE. Another green light appears increasingly within reach for AstraZeneca’s Emerald program after a combo regimen featuring the company’s immunotherapy duo, Imfinzi and Imjudo, showed benefit in certain liver cancer patients. Results from the phase 3 Emerald-3 trial showed that the combination, paired with transarterial chemoembolizaton (TACE) and Lenvima, significantly improved progression-free survival (PFS) versus TACE alone in patients with unresectable locoregional hepatocellular carcinoma. Lenvima is a multikinase inhibitor sold by Merck & Co. and Eisai.But whether AZ has struck gold with Emerald-3 remains to be seen. Overall survival (OS), a secondary endpoint that will be a key consideration for the FDA, was immature at the interim analysis, although AZ highlighted a trend toward improvement in its April 2 announcement. In two ways, the Emerald-3 showing draws a resemblance to AZ’s Emerald-1 readout in the same locoregional treatment setting among liver cancer patients eligible for TACE. Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the risk of progression or death by 23% versus TACE alone. At that time, OS was also immature, and AZ’s oncology R&D chief, Susan Galbraith, Ph.D., flagged that patient survival data are crucial in this locoregional setting. Case in point: Despite a PFS win, Merck & Co. last year abandoned hopes for a similar liver cancer approval for its Keytruda-Lenvima-TACE regimen after it failed to improve OS compared with TACE alone.Emerald-1 still hasn’t reported its final OS data, and the study has not graduated to the regulatory submission batch in AZ’s most recent earnings report in February. In addition, like Emerald-1, Emerald-3 has a second experimental arm. In this cohort, Imfinzi, Imjudo and TACE—without Lenvima—showed what AZ called “strong trends” toward improved PFS and OS, although these analyses were not formally tested. Previously, in Emerald-1, only the Avastin-containing triplet beat TACE, while Imfinzi-TACE failed to move the needle. AZ is discussing the latest Emerald-3 data with global regulatory authorities while waiting for final results from the trial’s key secondary endpoints, Galbraith said in an April 2 statement.As for Emerald-1, an AZ spokesperson said the company will share additional data in the future and will update its regulatory discussion plans as appropriate. Liver cancer helped AZ’s CTLA-4 agent Imjudo break into the market in 2022 as part of a combination with Imfinzi in unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. Patients who are eligible for embolization have an earlier stage of disease. In 2026, more than 200,000 patients belong to this category, according to data cited by AZ—however, most patients who receive the procedure experience progression or recurrence within six to ten months.The British pharma also has a third Emerald. Called Emerald-2, the phase 3 study is testing Imfinzi with Avastin in adjuvant liver cancer, with its data expected in the second half of 2026. As for the Imfinzi-Imjudo duo, AZ also expects readouts this year from its Nile trial in first-line metastatic bladder cancer and from its Volga study assessing a neoadjuvant regimen in cisplatin-ineligible muscle-invasive bladder cancer. Both will need to live up to the high expectations set by the combination of Merck & Co.’s Keytruda and Pfizer and Astellas’ antibody-drug conjugate Padcev.For AZ’s broader oncology portfolio, the company is bracing for an upcoming FDA advisory committee meeting that will dig into two separate applications for its oral SERD med camizestrant and the AKT inhibitor Truqap. The high-stakes first-line non-small cell lung cancer readout for Daiichi Sankyo-partnered Datroway from the Avanzar trial is also expected this year.

临床3期临床结果抗体药物偶联物临床2期

2026-04-02

·ioncology

2026 SGO年会快速口头报告：四场会议内容精粹

2026年美国妇科肿瘤学会（SGO）年会设置了丰富的学术板块，包括大师班（Masterclass）、科学全体会议（Scientific Plenary）、专题论坛（Focused Forum）、行业卫星会（ISS）、快速口头报告（Rapid-Fire Oral）、壁报导览（Poster Tour）和互动工作坊（Workshop）等类型。快速口头报告环节以简短高效的形式，呈现遗传学、手术、转化医学、健康差异等领域的最新研究数据。本文介绍四场快速口头报告的内容。快速口头报告I: 遗传学、预防与手术（Genetics, Prevention and Surgery）时间：2026年4月11日（星期六）3:00 - 4:00 PM 地点：104号厅主持人：Kaitlin Dwyer, PA-C (MD安德森癌症中心), Melissa Frey, MD, MS (威尔康奈尔医学院) 胰高血糖素样肽-1受体激动剂与非糖尿病肥胖女性的肥胖相关癌症累积发病率降低相关 Glucagon-Like Peptide-1 Receptor Agonists Are Associated With a Reduced Cumulative Incidence of Obesity-Associated Cancers in Obese Non-Diabetic Women 讲者: Heng-Cheng Hsu, MD (休斯顿卫理公会医院) 基于实验室研究注册库，子宫内膜癌患者（诊断年龄在65岁以下和以上）的生殖系致病性变异发生率 Prevalence of germline pathogenic variants in patients with endometrial cancer diagnosed before and after 65 years old within a laboratory-based research registry 讲者: Kieran Seay, MD/PhD (匹兹堡大学医学中心) 在低人群患病率下，对子宫内膜上皮内瘤变进行错配修复蛋白免疫组化检测诊断林奇综合征具有成本效益 Immunohistochemistry for mismatch repair protein expression in endometrial intraepithelial neoplasia is cost effective to diagnose Lynch Syndrome at low population prevalence 讲者: Hadley Reid (布莱根妇女医院 / 麻省总医院) 针对BRCA1/2致病性变异携带者的群体教育干预随机可行性研究 A randomized feasibility study of group-based education intervention for BRCA1/2 pathogenic variant carriers 讲者: Isabel Beshar, MD, MPhil (MD安德森癌症中心) 宫颈拭子中TUBB6甲基化用于卵巢癌检测：初步性能 TUBB6 Methylation in Cervical Swabs for Ovarian Cancer Detection: Primarily Performance 讲者: Kuo-Min Su, MD, PhD (三军总医院，国防医学院) 多癌种早期检测在降低宫颈癌、卵巢癌和子宫内膜癌死亡率中的潜力 The Potential of Multi-Cancer Early Detection Tests for Reducing Cancer Mortality in Cervical, Ovarian, and Endometrial Cancers 讲者: Elle Grevstad, PhD (Exact Sciences) 要点总结讲者: Lee-may Chen, MD (加州大学旧金山分校海伦·迪勒家庭综合癌症中心) 问答环节术中包膜破裂对I期黏液性卵巢癌的预后影响 Prognostic impact of intraoperative capsule rupture in stage I mucinous ovarian carcinoma 讲者: Christian Dagher, MD MSc (宾夕法尼亚大学医院) I期恶性卵巢生殖细胞肿瘤患者保留生育功能的卵巢囊肿切除术的应用及治疗结局 Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors 讲者: Delanie Ludmir, MD Candidate (哥伦比亚大学瓦格洛斯内外科医学院) 鞘内注射吗啡联合术中利多卡因输注vs硬膜外麻醉联合术后PCA用于剖腹探查术患者：一项随机对照试验 Comparing Intrathecal Morphine with Intraoperative Lidocaine Infusion to Epidural Anesthesia with Postoperative PCA for Patients Undergoing Exploratory Laparotomy: A Randomized Controlled Trial 讲者: Alexander Cohen, MD (拉什大学医学中心) 要点总结讲者: Katherine Kurnit, MD, MPH (芝加哥大学) 问答环节快速口头报告II：医疗差异与医疗可及性、患者考量（Disparities and Access to Care, Patient Considerations）时间：2026年4月11日（星期六）4:30 - 5:30 PM 地点：104号厅主持人：Brooke Sanders, MD (圣路易斯华盛顿大学) 波多黎各宫颈腺癌患者的HPV基因分型：对疫苗覆盖和监测的启示 HPV Genotyping in adenocarcinoma of the cervix in patients living in Puerto Rico: Implications for Vaccine Coverage and Surveillance 讲者: Ana Rosario Santos, MD, MPH (迈阿密大学西尔维斯特综合癌症中心) 打破生存差距：临床试验作为妇科癌症结局的平衡器 Breaking the Survival Gap: Clinical Trials as Equalizers in Gynecologic Cancer Outcomes 讲者: Rachael Piver, MD (佐治亚医学院) 实体器官移植后宫颈癌筛查率低的相关因素 Factors associated with low uptake of cervical cancer screening post-solid organ transplant 讲者: Katherine Cooke, MD (明尼苏达大学) 改善医疗可及性：医生和高级执业医师在宫颈癌前病变诊断中的表现 Improving Access to Care: Physician and Advanced Practice Provider Performance in Cervical Preinvasive Disease Diagnosis 讲者: Alexandra North, MD (阿拉巴马大学伯明翰分校) 手术之痛：妇科肿瘤医生工作相关疼痛与损伤 Surgery Hurts: The Burden of Work-Related Pain and Injuries Among Gynecologic Oncologists 讲者: Elizabeth Adams, MD (斯坦福大学) 要点总结讲者: Jennifer Young Pierce, MD, MPH (南阿拉巴马大学米切尔癌症研究所) 问答环节强制完成生命末期表格可降低妇科肿瘤患者的住院死亡率 Mandatory Completion of End-of-Life Forms (eMOLSTs) Reduces Inpatient Mortality in Gynecologic Oncology Patients 讲者: Antalya Jano, MD (纽约大学格罗斯曼医学院) 支持高风险I-II期子宫内膜样子宫内膜癌辅助治疗升级的因素：一项倾向性评分加权研究 Factors Supporting Adjuvant Treatment Escalation in High-Risk Stage I-II Endometrioid Endometrial Carcinoma: A Propensity Score Weighed Investigation 讲者: Samantha Leite, MD (国家首都联盟) 一项倾向性评分加权分析发现：在低级别I期子宫内膜样卵巢癌、输卵管癌和腹膜癌患者中，辅助化疗对比观察有相似生存结局 Similar Survival Outcomes Following Adjuvant Chemotherapy Versus Observation in Low-Grade, Stage I Endometrioid Ovarian, Tubal and Peritoneal Carcinoma: A Propensity Score Weighted Analysis 讲者: Samantha Leite, MD (国家首都联盟) 基于分子分型预测子宫内膜癌患者接受“保留生育功能孕激素治疗”的疗效 Prediction of Response to Fertility Preserving Progestin Therapy for Endometrial Cancer Based on Molecular Subtype 讲者: Oleksandra Dzyubak, MD (多伦多大学) 要点总结讲者: Alexander Melamed, MD MPH (麻省总医院 / 哈佛医学院) 问答环节快速口头报告III：转化医学与抗体药物偶联物（Translational and ADC）时间：2026年4月12日（星期日）12:00 - 1:00 PM 地点：104号厅主持人：Sarah Ferguson, MD (玛格丽特公主医院), Fiorella Reyes Baez, MD (波多黎各大学医学院) 整合单细胞分析揭示TNFAIP3为乳酰化调控卵巢癌化疗耐药的关键因子 Integrated Single-cell Profiling Identifies TNFAIP3 as a Lactylation-Driven Regulator of Chemoresistance in Ovarian Cancer 讲者: 黄慧霞 (复旦大学附属肿瘤医院) CCNE1扩增对无BRCA突变的新诊断卵巢癌患者无进展生存期和总生存期的影响 Impact of CCNE1 amplification on progression-free and overall survival among patients with newly diagnosed ovarian cancer without a BRCA mutation 讲者: Stephen Graves, MD (纪念斯隆凯特琳癌症中心) 在尼拉帕利和多斯塔利单抗治疗复发性或持续性子宫浆液性癌的II期试验中分析免疫组库特征 Profiling the Immune Repertoire in a Phase II Trial of Niraparib and Dostarlimab in Recurrent or Persistent Uterine Serous Carcinomas 讲者: Caprice Eisele, BS (俄亥俄州立大学) 卡铂联合CHK1抑制剂在临床前小鼠模型中克服高级别浆液性卵巢癌铂耐药 Combination of carboplatin and CHK1 inhibition to overcome platinum resistance in high grade serous ovarian cancer in preclinical mouse models 讲者: Mackenzie Cummings, MD (南阿拉巴马大学米切尔癌症研究所) 要点总结讲者: Tyler Hillman, MD, PhD (加州大学圣地亚哥分校) 问答环节索米妥昔单抗联合卡铂治疗叶酸受体α表达的复发性铂敏感卵巢癌 Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer 讲者: Gottfried Konecny, MD (加州大学洛杉矶分校医学系) 抗体药物偶联物（ADC）靶点的全面分析揭示了子宫内膜癌的组织学特异性和共表达模式 Comprehensive Profiling of antibody-drug conjugate (ADC) Targets Reveals Histology-Specific and Co-Expression Patterns in Endometrial Carcinoma 讲者: Kosuke Shigematsu, MD (埼玉医科大学国际医疗中心) 新型B7H3 ADC (DB1311/BNT324)单药用于经治晚期宫颈癌或铂耐药复发性卵巢癌患者的全球1/2期研究：按既往治疗分层的结局 A global, phase 1/2 study of DB1311/BNT324 (a novel B7H3 ADC) monotherapy in patients with previously treated advanced cervical cancer or platinum-resistant recurrent ovarian cancer: Outcomes by prior treatment 讲者: Ira Winer, MD, PhD (韦恩州立大学) 高级别浆液性癌中FOLR表达的表观遗传驱动因素 Epigenetic drivers of FOLR expression in high grade serous carcinoma 讲者: Katharine Linder, MD (科罗拉多大学安舒茨医学校区) 要点总结讲者: Debra Richardson, MD (俄克拉荷马大学健康科学中心) 问答环节快速口头报告IV：长期试验结局（Long-term Trial Outcomes）时间：2026年4月13日（星期一）9:30 - 10:30 AM 地点：208号厅主持人：David Cantu De Leon, MD, PHD (国家癌症研究所), Roisin O'Cearbhaill, MD (纪念斯隆凯特琳癌症中心) 来自ENGOT-ov65/KEYNOTE-B96 III期试验（帕博利珠单抗对比安慰剂联合紫杉醇±贝伐珠单抗治疗铂耐药复发卵巢癌）的患者报告结局 Patient-reported outcomes from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab versus placebo plus paclitaxel, with or without bevacizumab, in platinum-resistant recurrent ovarian cancer 讲者: Emese Zsiros, MD, PhD (罗斯威尔公园综合癌症中心) 联合PP2A抑制与PD-1阻断（LB-100和多斯塔利单抗）治疗卵巢透明细胞癌 Combination PP2A inhibition and PD-1 blockade with LB-100 and dostarlimab in ovarian clear cell carcinoma 讲者: Helen Clark, MD (德克萨斯大学MD安德森癌症中心) 妇科肿瘤患者接受帕博利珠单抗治疗的免疫相关不良事件：临床试验证据与现实世界经验 Immune-related adverse effects in gynecologic oncology patients on pembrolizumab: trial evidence vs real-world experience 讲者: Ellery Sarosi, MD (密歇根大学) 来自PRIMA/ENGOT-OV26/GOG-3012试验（尼拉帕利一线维持治疗新诊断晚期卵巢癌）最终分析的患者报告结局：基于同源重组缺陷状态的结果 Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: results from the homologous recombination-deficient subgroup 讲者: Floor Backes, MD (俄亥俄州立大学) 对于复发性颗粒细胞瘤患者，二次肿瘤细胞减灭术后辅助治疗的效果 Effect of adjuvant treatment after secondary cytoreductive surgery in patients with recurrent granulosa cell tumor 讲者: Elio Tahan, MD (MD安德森癌症中心) 要点总结讲者: Premal Thaker, MD (圣路易斯华盛顿大学) 问答环节超越Sedlis标准：验证I期宫颈鳞癌和腺癌的组织学特异性风险因素 Beyond Sedlis: Validation of histology-specific risk factors for stage I cervical squamous cell carcinoma and adenocarcinoma 讲者: Tullia Rushton, MD (厄兰格医院) 1b/2a期随机、双盲研究显示新型抗病毒阴道插入物（药物递送装置）ABI-2280治疗持续性高危/致癌HPV感染的潜力 Phase 1b/2a randomized, double-blind study demonstrates potential of ABI-2280, a novel antiviral vaginal insert for the treatment of persistent high-risk/oncogenic HPV infection 讲者: Warner Huh, MD, FCOG, FACS (阿拉巴马大学伯明翰分校) 局部晚期宫颈癌对大分割放疗的病理反应 Pathologic response to hypofractionation in locally advanced cervical cancer 讲者: David Cantu De Leon, MD, PHD (国家癌症研究所) IVB期宫颈癌中孤立性远处淋巴结转移的预后意义 Prognostic significance of distant lymph node metastases alone in stage IVB cervical cancer 讲者: Christian Dagher, MD MSc (宾夕法尼亚大学医院) 要点总结讲者: Dana Chase, MD (加州大学洛杉矶分校大卫·格芬医学院) 问答环节（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床研究

2026-04-02

·Firstwordpharma

AstraZeneca touts quadruplet approach in earlier-stage liver cancer

AstraZeneca said a treatment regimen anchored by its PD-L1 inhibitor Imfinzi (durvalumab) and anti-CTLA-4 antibody Imjudo (tremelimumab) succeeded in the Phase III EMERALD-3 trial in patients with hepatocellular carcinoma (HCC).The study is seen as an important test of whether using every available treatment strategy right from the start can improve outcomes for liver cancer patients, though some key opinion leaders (KOLs) worry such an aggressive approach may be too harsh for routine practice and could leave patients with fewer treatment options later on.EMERALD-3 includes 760 patients with unresectable, locoregional HCC who are eligible for embolisation. Participants received either the STRIDE regimen – consisting of single-dose Imjudo plus regular-interval Infinzi – with transarterial chemoembolisation (TACE); the same immunotherapy backbone plus Eisai's VEGF receptor inhibitor Lenvima (lenvatinib) and TACE; or TACE alone.Eye on OSAstraZeneca said the quadruplet approach achieved significant and clinically meaningful improvement on the primary endpoint of progression-free survival (PFS), compared to TACE alone. Overall survival (OS), a key secondary endpoint, showed a trend in favour of this combination as well, but data are still immature.Although it hasn't yet been formally tested, AstraZeneca said early data from the treatment arm that didn't receive Lenvima revealed "strong trends" toward improved PFS and OS.The trial will continue to follow OS in both investigational arms, though the company is optimistic. Susan Galbraith, head of oncology haematology R&D at AstraZeneca, said EMERALD‑3 builds on the Phase III HIMALAYA results, "where the STRIDE regimen has already demonstrated durable overall survival benefit."HIMALAYA tested the combination of Imfinzi and Imjudo in HCC patients with advanced, unresectable disease. Long-term data presented at the European Society for Medical Oncology (ESMO) conference in 2024 showed that nearly 20% of patients given the combination were alive at five years, roughly double the OS rate with Bayer's Bayer's Nexavar (sorafenib).However, earlier efforts to combine Imfinzi with TACE got a mixed reception in the Phase III EMERALD‑1 study a few years ago, where PFS benefit depended on the inclusion of Roche's Avastin (bevacizumab).Toxicity concernsMeanwhile, AstraZeneca said the safety profile for each combination in EMERALD-3 was consistent with the known profiles of each medicine, adding there were no new safety findings. More details will be shared at a forthcoming medical meeting and shared with global regulatory authorities.KOLs interviewed for a FirstWord report voiced serious concerns about toxicity especially given the aggressive use of agents targeting PD-L1, CTLA-4 and VEGF pathways in a patient population that often has cirrhosis or compromised liver function."It will be interesting to see how patients tolerate this," said one US-based KOL. "I think one of the issues with EMERALD-1 that we saw was that there were a lot of dropouts…I just wonder about the kind of additional toxicities that we might see when we keep adding therapies. That being said, you might get a prolonged response in some of these patients."

临床结果临床3期临床2期

100 项与贝伐珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06409	贝伐珠单抗	L01XC07	DB00112

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
不可切除的肝细胞癌	日本	Chugai Pharmaceutical Co., Ltd.	2020-09-25
肝细胞癌	美国	Genentech, Inc.	2020-05-29
复发性胶质母细胞瘤	美国	Genentech, Inc.	2020-05-29
复发性原发性腹膜癌	美国	Genentech, Inc.	2014-11-14
卵巢癌	日本	Chugai Pharmaceutical Co., Ltd.	2013-11-22
胶质瘤	日本	Chugai Pharmaceutical Co., Ltd.	2013-06-14
乳腺癌	日本	Chugai Pharmaceutical Co., Ltd.	2011-09-26
结直肠癌	日本	Chugai Pharmaceutical Co., Ltd.	2009-09-18
转移性肾细胞癌	美国	Genentech, Inc.	2009-07-31
胶质母细胞瘤	美国	Genentech, Inc.	2009-05-05
转移性结直肠癌	美国	Genentech, Inc.	2009-05-05
节细胞神经胶质瘤	日本	Chugai Pharmaceutical Co., Ltd.	2007-04-18
非鳞状非小细胞肺癌	美国	Genentech, Inc.	2006-10-11
输卵管癌	欧盟	Roche Registration GmbH	2005-01-12
输卵管癌	冰岛	Roche Registration GmbH	2005-01-12
输卵管癌	列支敦士登	Roche Registration GmbH	2005-01-12
输卵管癌	挪威	Roche Registration GmbH	2005-01-12
转移性乳腺癌	欧盟	Roche Registration GmbH	2005-01-12
转移性乳腺癌	冰岛	Roche Registration GmbH	2005-01-12
转移性乳腺癌	列支敦士登	Roche Registration GmbH	2005-01-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期子宫内膜癌	临床3期	美国	National Cancer Institute	2026-01-27
复发性子宫内膜癌	临床3期	美国	National Cancer Institute	2026-01-27
晚期头颈癌	临床3期	美国	National Cancer Institute	2023-03-13
头颈癌转移	临床3期	美国	National Cancer Institute	2023-03-13
局部晚期头颈部皮肤鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
鼻咽癌	临床3期	美国	National Cancer Institute	2023-03-13
鼻咽鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
口咽肿瘤	临床3期	美国	National Cancer Institute	2023-03-13
复发性咽部鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13
复发性头颈部鳞状细胞癌	临床3期	美国	National Cancer Institute	2023-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


IMbrave150 (AACR2026)	N/A	晚期肝细胞癌一线	3,948	Atezolizumab + Bevacizumab	醖夢淵願糧積鹽獵蓋蓋(選鏇觸範鬱築鹽淵憲繭) = The risk of developing predefined adverse events was similar between regimens with nonsignificant RD 餘鑰糧鬱範簾範願醖範 (夢網鏇遞壓壓餘蓋構選 ) 更多	积极	2026-04-21
				Nivolumab + Ipilimumab
NCT00720512 (BEBYP, AACR2026)	临床3期	转移性结直肠癌二线 EPAS-1 \| IL-8 \| VEGF-A ... 更多	132	bevacizumab+CHT	窪製夢觸鏇鹽膚襯鹽鏇(顧艱觸築醖築膚膚選壓) = 窪蓋鑰廠選襯壓襯淵網糧築淵鹹簾鹹鹽製顧膚 (鬱蓋築餘選襯積構艱獵 ) 更多	积极	2026-04-20
				CHT alone	窪製夢觸鏇鹽膚襯鹽鏇(顧艱觸築醖築膚膚選壓) = 艱壓衊夢繭醖觸襯築積糧築淵鹹簾鹹鹽製顧膚 (鬱蓋築餘選襯積構艱獵 ) 更多
SWOG S0819 (AACR2026)	临床3期	非小细胞肺癌 Serial CTRS	1,275	Cetuximab + carboplatin/paclitaxel	鬱觸鏇夢築廠壓壓網齋(築範選襯齋遞築憲範夢) = BOR achieved 35% (33–37%) power 壓選憲糧簾襯壓網夢選 (鹽選築齋鹽鏇醖獵鹹鑰 ) 更多	积极	2026-04-20
				Bevacizumab + cetuximab + carboplatin/paclitaxel
NCT02873962 (CTgov)	临床2期	复发性卵巢癌 \| 腹膜癌 \| 输卵管癌	72	Nivolumab+Rucaparib+Bevacizumab (Cohort 2: Nivolumab With Bevacizumab and Rucaparib)	夢膚蓋壓壓願衊繭獵窪 = 網範遞積簾構膚壓窪憲憲憲齋繭鏇範鏇鏇膚構 (獵衊鏇觸衊鹹廠窪壓選, 選糧遞鹽餘廠糧構獵鹹 ~ 艱鬱選艱繭餘蓋襯積範) 更多	-	2026-04-01
				Nivolumab+Rucaparib+Bevacizumab (Cohort 3: Nivolumab With Bevacizumab and Rucaparib)	襯齋遞艱願積艱鑰淵選 = 鑰鹽鬱簾鹹獵獵蓋鏇夢繭窪廠醖觸鬱選鹽選顧 (築範醖築範鏇壓憲醖願, 獵積網鑰鏇艱築觸簾簾 ~ 鏇壓憲構顧築簾醖廠醖) 更多
NCT01743950 (CTgov)	临床2期	复发性胶质瘤 \| 胶质瘤 \| 复发性恶性胶质瘤	49	PRDR+Bevacizumab (Bevacizumab-naïve With Recurrent IDH Wildtype High Grade Glioma)	鏇鹹積窪獵獵獵網範餘(鏇繭製願餘糧繭淵餘構) = 願襯夢範廠糧壓廠襯鬱遞淵遞蓋獵獵鹽糧糧顧 (獵積繭鹽網選齋選顧顧, 6.0) 更多	-	2026-03-25
				PRDR+Bevacizumab (Bevacizumab-exposed With Refractory Recurrent IDH Wildtype High Grade Glioma)	鏇鹹積窪獵獵獵網範餘(鏇繭製願餘糧繭淵餘構) = 築製襯淵築遞蓋衊糧網遞淵遞蓋獵獵鹽糧糧顧 (獵積繭鹽網選齋選顧顧, 4.8) 更多
NCT02971501 (CTgov)	临床2期	EGFR阳性非小细胞肺癌 \| EGFR-T790M 突变非小细胞肺癌 \| 转移性非小细胞肺癌 ... 更多	7	Computed Tomography+Bevacizumab+Osimertinib (Arm I (Osimertinib, Bevacizumab))	積窪鹹壓壓壓顧餘夢網(簾築蓋積衊製艱糧廠憲) = 艱選獵鏇餘簾鑰膚壓簾鹽遞獵範夢願網膚鬱積 (淵鬱選鬱糧糧窪糧糧築, 醖鑰積製窪糧鹽範製遞 ~ 淵壓願廠獵觸構繭膚網) 更多	-	2026-03-17
				Osimertinib (Arm II (Osimertinib))	積窪鹹壓壓壓顧餘夢網(簾築蓋積衊製艱糧廠憲) = 醖衊獵襯艱蓋壓範齋網鹽遞獵範夢願網膚鬱積 (淵鬱選鬱糧糧窪糧糧築, 鬱積糧壓鹽淵醖構膚鹽 ~ 襯糧淵築糧艱餘鑰網鹹) 更多
NCT05844046 (MONTBLANC, Pubmed \| Ther Adv Med Oncol)	临床2期	不可切除的肝细胞癌 programmed cell death ligand 1 \| cytotoxic T-lymphocyte-associated antigen-4 \| vascular endothelial growth factor	168	Durvalumab + Tremelimumab + Bevacizumab	壓鹽蓋範醖觸蓋鹽鑰鑰(廠齋遞繭鬱繭齋膚艱齋) = 齋積願繭衊襯齋構積齋餘淵齋廠鏇襯構襯廠鏇 (顧壓衊餘鏇鹽艱積鬱憲 )	积极	2026-03-01
				Durvalumab + Tremelimumab	願選範顧膚鹹簾憲簾膚(鏇選製範積築鏇繭艱觸) = 衊蓋餘繭簾衊夢鑰廠獵網淵繭鑰憲衊醖鑰窪鹹 (鬱夢構鹽壓鏇淵衊獵膚 ) 更多
MITORT3 (ESGO2026)	N/A	卵巢癌	41	SABR+Bevacizumab	壓遞窪積鹹襯繭齋糧觸(壓願夢鬱憲網網衊壓願) = 鏇觸簾鑰齋壓繭顧構範遞膚醖繭衊製獵網淵積 (獵鏇窪憲鏇觸鏇獵製壓 ) 更多	积极	2026-02-28
ESGO2026	N/A	-	75	Bevacizumab-containing regimens	齋積壓選鹹糧膚廠選願(窪願蓋築觸鹹艱鑰艱願) = 膚繭鹹願淵觸鑰繭襯獵鹽鑰簾鬱艱繭鏇醖蓋壓 (選築餘鹹餘構鹹鹽遞範 ) 更多	积极	2026-02-28
				Chemotherapy alone	齋積壓選鹹糧膚廠選願(窪願蓋築觸鹹艱鑰艱願) = 糧簾積繭鏇簾鏇夢餘窪鹽鑰簾鬱艱繭鏇醖蓋壓 (選築餘鹹餘構鹹鹽遞範 ) 更多
ESGO2026	N/A	卵巢高级别浆液性腺癌	101	Bevacizumab (BRCA wild-type)	鬱齋醖網襯顧製鏇獵夢(網選糧餘夢遞膚繭窪憲) = 淵齋齋淵蓋襯範糧膚糧簾鹽憲襯築構簾廠鹽餘 (鑰憲壓餘顧製廠觸鏇艱 ) 更多	积极	2026-02-28
				Non-bevacizumab (BRCA wild-type)	鬱齋醖網襯顧製鏇獵夢(網選糧餘夢遞膚繭窪憲) = 膚顧簾積鬱鹽觸齋網艱簾鹽憲襯築構簾廠鹽餘 (鑰憲壓餘顧製廠觸鏇艱 ) 更多